Anticipated Milestones: ENPP1 Deficiency: Start of FDA pivotal trial meetings-Q1 2023; Initiation of ENERGY-1 – Phase 1b clinical trial of INZ-701 to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infants-Q2 2023; Interim clinical data from ongoing Phase 1/2 trial in adults-Q3 2023; Initiation of pivotal trial in pediatric patients, subject to regulatory approval-Q3 2023; Start of EMA protocol assistance meetings-Q4 2023. ABCC6 Deficiency: Interim clinical data from ongoing Phase 1/2 trial in adults-Q4 2023; Initiation of Phase 2/3 clinical trial, subject to regulatory approval-2024
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INZY:
